Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

CARsgen Therapeutics Holdings Ltd. (2171) Stock Price & Analysis

2171 Stock Chart & Stats

HK$10.63-HK$0.32(-2.92%)
At close: 4:00 PM GMT+8
HKD 12HKD 14HKD 163 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
HKD 10.63 - HKD 11.10
52-Week Range
HKD 10.47 - HKD 28.60
Previous Close
HKD 10.95
Volume
3.37M
Average Volume (3M)
1.59M
Market Cap
HKD 6.32B
Enterprise Value
HKD 6.32B
Total Cash (Recent Filing)
HKD 1.40B
Total Debt (Recent Filing)
HKD 71.98M
Price to Earnings (P/E)
―
Beta
1.45
Next Earnings
Mar 23, 2027 (Est.)
EPS Estimate
-0.18
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Gross Profit Growth

The sharp 2025 revenue increase, together with a positive gross profit, indicates improving commercial traction and product economics. If sustained, this expanding revenue base can provide greater operating leverage and gradually improve the company’s ability to fund its development platform.

Lower Debt And Conservative Leverage

The substantial reduction in debt lowers fixed financial obligations and reduces balance-sheet pressure while the company continues investing in research and development. Lower leverage provides more flexibility to allocate capital toward clinical programs and commercialization rather than servicing borrowings.

Substantial Asset And Equity Base

A sizeable asset base and remaining equity provide the company with financial resources to continue advancing its CAR-T pipeline and commercial activities. This capital cushion is strategically useful in biotechnology, where product development and regulatory timelines require sustained investment.

Bears Say

Persistent Operating Losses

Large operating and net losses show that the business has not yet converted improving revenue into sustainable profitability. Continued losses can consume capital, constrain investment choices, and leave future earnings dependent on successful product development or additional funding.

Negative Operating Cash Flow

The company still does not fund operations internally, even though cash burn improved year over year. Persistent negative operating cash flow increases reliance on financing and makes the durability of research, development, and commercialization spending more dependent on external capital.

Eroding Equity Base

The sustained reduction in equity is consistent with repeated losses and cash burn, weakening the company’s financial flexibility over time. If the decline continues, CARsgen may have fewer internally funded resources for clinical development and greater dependence on financing.

CARsgen Therapeutics Holdings Ltd. News

2171 FAQ

What was CARsgen Therapeutics Holdings Ltd.’s price range in the past 12 months?
CARsgen Therapeutics Holdings Ltd. lowest stock price was HK$10.47 and its highest was HK$28.60 in the past 12 months.
What is CARsgen Therapeutics Holdings Ltd.’s market cap?
CARsgen Therapeutics Holdings Ltd.’s market cap is HK$6.32B.
When is CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date?
CARsgen Therapeutics Holdings Ltd.’s next earnings report is estimated for Mar 23, 2027 (not yet confirmed), which is in 142 days.
How were CARsgen Therapeutics Holdings Ltd.’s earnings last quarter?
CARsgen Therapeutics Holdings Ltd. released its earnings results on Aug 19, 2026. The company reported -HK$0.152 earnings per share for the quarter, beating the consensus estimate of -HK$0.222 by HK$0.07.
Is CARsgen Therapeutics Holdings Ltd. overvalued?
According to Wall Street analysts CARsgen Therapeutics Holdings Ltd.’s price is currently Undervalued.
Does CARsgen Therapeutics Holdings Ltd. pay dividends?
CARsgen Therapeutics Holdings Ltd. does not currently pay dividends.
What is CARsgen Therapeutics Holdings Ltd.’s EPS estimate?
CARsgen Therapeutics Holdings Ltd.’s EPS estimate is -0.18.
How many shares outstanding does CARsgen Therapeutics Holdings Ltd. have?
CARsgen Therapeutics Holdings Ltd. has 594,248,900 shares outstanding.
What happened to CARsgen Therapeutics Holdings Ltd.’s price movement after its last earnings report?
CARsgen Therapeutics Holdings Ltd. reported an EPS of -HK$0.152 in its last earnings report, beating expectations of -HK$0.222. Following the earnings report the stock price went up 1.361%.
Which hedge fund is a major shareholder of CARsgen Therapeutics Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2171
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology